Zhongzhi Pharmaceutical Holdings Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Zhongzhi Pharmaceutical Holdings.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	12.6%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

Apr 21

Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) Prospects Need A Boost To Lift Shares

Feb 01

These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well

May 24

Is Zhongzhi Pharmaceutical Holdings (HKG:3737) A Risky Investment?

Aug 26

Zhongzhi Pharmaceutical Holdings (HKG:3737) Has A Pretty Healthy Balance Sheet

Apr 28

These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well

Jun 11

Investors Met With Slowing Returns on Capital At Zhongzhi Pharmaceutical Holdings (HKG:3737)

May 06

Zhongzhi Pharmaceutical Holdings (HKG:3737) Strong Profits May Be Masking Some Underlying Issues

Apr 21

Do Zhongzhi Pharmaceutical Holdings's (HKG:3737) Earnings Warrant Your Attention?

Mar 29

The Zhongzhi Pharmaceutical Holdings (HKG:3737) Share Price Has Gained 50% And Shareholders Are Hoping For More

Mar 05

Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?

Feb 15

What Is The Ownership Structure Like For Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)?

Jan 14

Would Zhongzhi Pharmaceutical Holdings Limited (HKG:3737) Be Valuable To Income Investors?

Dec 27

If You Like EPS Growth Then Check Out Zhongzhi Pharmaceutical Holdings (HKG:3737) Before It's Too Late

Dec 14

Did You Miss Zhongzhi Pharmaceutical Holdings' (HKG:3737) 31% Share Price Gain?

Nov 30

Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?

Nov 17

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Zhongzhi Pharmaceutical Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:3737 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	2,050	163	-70	102	N/A
9/30/2023	2,062	164	18	168	N/A
6/30/2023	2,074	164	106	234	N/A
3/31/2023	1,950	135	151	259	N/A
12/31/2022	1,826	106	195	285	N/A
9/30/2022	1,766	84	147	263	N/A
6/30/2022	1,706	63	98	242	N/A
3/31/2022	1,726	57	44	210	N/A
12/31/2021	1,747	52	-9	178	N/A
9/30/2021	1,750	93	-46	132	N/A
6/30/2021	1,753	133	-83	86	N/A
3/31/2021	1,678	136	-54	90	N/A
12/31/2020	1,604	139	-25	93	N/A
9/30/2020	1,524	133	29	120	N/A
6/30/2020	1,444	128	82	147	N/A
3/31/2020	1,393	121	92	157	N/A
12/31/2019	1,342	115	102	168	N/A
9/30/2019	1,282	106	88	160	N/A
6/30/2019	1,221	97	75	152	N/A
3/31/2019	1,182	91	39	116	N/A
12/31/2018	1,142	85	4	80	N/A
9/30/2018	1,106	82	-15	55	N/A
6/30/2018	1,070	79	-35	29	N/A
3/31/2018	1,007	74	-19	40	N/A
12/31/2017	945	70	-2	51	N/A
9/30/2017	874	65	N/A	52	N/A
6/30/2017	803	60	N/A	53	N/A
3/31/2017	767	57	N/A	51	N/A
12/31/2016	730	54	N/A	49	N/A
9/30/2016	715	52	N/A	41	N/A
6/30/2016	700	50	N/A	34	N/A
3/31/2016	694	65	N/A	45	N/A
12/31/2015	688	81	N/A	56	N/A
9/30/2015	671	91	N/A	80	N/A
6/30/2015	655	101	N/A	104	N/A
3/31/2015	625	94	N/A	113	N/A
12/31/2014	596	87	N/A	122	N/A
12/31/2013	483	38	N/A	45	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 3737's forecast earnings growth is above the savings rate (2%).

Earnings vs Market: Insufficient data to determine if 3737's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 3737's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 3737's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 3737's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 3737's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Zhongzhi Pharmaceutical Holdings Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Zhongzhi Pharmaceutical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023

Zhongzhi Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended June 30, 2023

Zhongzhi Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2022

Zhongzhi Pharmaceutical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2021

Recent updates

Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03

Zhongzhi Pharmaceutical Holdings Limited, Annual General Meeting, May 17, 2024

Chairman recently bought HK$4.0m worth of stock

Full year 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.13 in FY 2022)

Final dividend of HK$0.03 announced

Zhongzhi Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) Prospects Need A Boost To Lift Shares

Zhongzhi Pharmaceutical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023

Chairman recently bought HK$1.4m worth of stock

Zhongzhi Pharmaceutical Holdings Limited Approves Interim Dividend

Upcoming dividend of HK$0.06 per share at 8.8% yield

Chairman recently bought HK$467k worth of stock

First half 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.091 in 1H 2022)

Chairman recently bought HK$135k worth of stock

Chairman recently bought HK$955k worth of stock

First half 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.091 in 1H 2022)

Zhongzhi Pharmaceutical Holdings Limited Proposes Interim Dividend for the Six Months Ended 30 June 2023, Payable on 2 November 2023

Investor sentiment improves as stock rises 15%

Zhongzhi Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 23, 2023

Zhongzhi Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended June 30, 2023

These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well

Zhongzhi Pharmaceutical Holdings Limited Approves the Declaration and Payment of Special Dividend

Upcoming dividend of HK$0.09 per share at 5.4% yield

Full year 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.062 in FY 2021)

Zhongzhi Pharmaceutical Holdings Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Deputy GM & Executive Director recently bought HK$229k worth of stock

Is Zhongzhi Pharmaceutical Holdings (HKG:3737) A Risky Investment?

First half 2022 earnings released: EPS: CN¥0.091 (vs CN¥0.081 in 1H 2021)

Zhongzhi Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 25, 2022

Chairman recently bought HK$177k worth of stock

Zhongzhi Pharmaceutical Holdings (HKG:3737) Has A Pretty Healthy Balance Sheet

Chairman recently bought HK$448k worth of stock

Less than half of directors are independent

Zhongzhi Pharmaceutical Holdings Limited, Annual General Meeting, May 20, 2022

Investor sentiment improved over the past week

Chairman recently bought HK$925k worth of stock

Investor sentiment improved over the past week

Chairman recently bought HK$1.8m worth of stock

Zhongzhi Pharmaceutical Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2021

Investor sentiment improved over the past week

First half 2021 earnings released: EPS CN¥0.081 (vs CN¥0.086 in 1H 2020)

These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well

Investors Met With Slowing Returns on Capital At Zhongzhi Pharmaceutical Holdings (HKG:3737)

Zhongzhi Pharmaceutical Holdings (HKG:3737) Strong Profits May Be Masking Some Underlying Issues

Full year 2020 earnings released: EPS CN¥0.17 (vs CN¥0.14 in FY 2019)

Do Zhongzhi Pharmaceutical Holdings's (HKG:3737) Earnings Warrant Your Attention?

Full year 2020 earnings released: EPS CN¥0.17 (vs CN¥0.14 in FY 2019)

Investor sentiment deteriorated over the past week

Zhongzhi Pharmaceutical Holdings Limited to Report Fiscal Year 2020 Results on Mar 24, 2021

The Zhongzhi Pharmaceutical Holdings (HKG:3737) Share Price Has Gained 50% And Shareholders Are Hoping For More

Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?

New 90-day high: HK$1.76

What Is The Ownership Structure Like For Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)?

Would Zhongzhi Pharmaceutical Holdings Limited (HKG:3737) Be Valuable To Income Investors?

If You Like EPS Growth Then Check Out Zhongzhi Pharmaceutical Holdings (HKG:3737) Before It's Too Late

Did You Miss Zhongzhi Pharmaceutical Holdings' (HKG:3737) 31% Share Price Gain?

Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?

Upcoming Dividend of HK$0.051 Per Share

First half earnings released

First half earnings released

New 90-day high - HK$1.90

Zhongzhi Pharmaceutical Holdings Limited to Report First Half, 2020 Results on Aug 26, 2020

New 90-day high - HK$1.32

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies